Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10

HOS-112064 · Präparat HOS-093615

*Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported. ANTIPLATELETS Ticagrelor The mechanism of the interaction is Co-administration of REYATAZ CYP3A4 inhibition by atazanavir and/or with ticagrelor is not recommended ritonavir. due to potential increase in the antiplatelet activity of ticagrelor. Clopidogrel The mechanism of the interaction is Co-administration with clopidogrel CYP3A4 inhibition by atazanavir and is not recommended due to or/ritonavir. potential reduction of the antiplatelet activity of clopidogrel. Prasugrel The mechanism of the interaction is No dose adjustment is needed when CYP3A4 inhibition by atazanavir and prasugrel is co-administered with or/ritonavir. REYATAZ (with or without ritonavir).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 45–46

HOS-112168 · Präparat HOS-093615

45 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Prasugrel The mechanism of the interaction is No dose adjustment is needed CYP3A4 inhibition by atazanavir and when prasugrel is or/ritonavir. co-administered with REYATAZ (with or without ritonavir). ANTI-RETROVIRALS Protease inhibitors: The co-administration of REYATAZ/ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors. Therefore, such co- administration is not recommended. Ritonavir 100 mg once daily Atazanavir AUC: ↑250% (↑144% ↑403%)* Ritonavir 100 mg once daily is (atazanavir 300 mg once daily) Atazanavir Cmax: ↑120% (↑56% ↑211%)* used as a booster of atazanavir Atazanavir Cmin: ↑713% (↑359% pharmacokinetics. Studies conducted in HIV- ↑1 339%)* infected patients. *In a combined analysis, atazanavir 300 mg and ritonavir 100 mg (n = 33) was compared to atazanavir 400 mg without ritonavir (n = 28).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) prasugrel (HOS-112066) ritonavir (HOS-084521)

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 15–16

HOS-116363 · Präparat HOS-094447

15 ANTIBIOTIC Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when 500 mg twice daily clarithromycin Cmin ↑ 174% clarithromycin is combined with clarithromycin Cmax ↑ 26% boosted PREZISTA. # darunavir AUC ↓ 13% # darunavir Cmin ↑ 1% For patients with renal impairment # the Summary of Product darunavir Cmax ↓ 17% Characteristics for clarithromycin 14-OH-clarithromycin concentrations should be consulted for the were not detectable when combined with recommended dose. PREZISTA/ritonavir. (↑ clarithromycin from CYP3A inhibition and possible P-gp inhibition) ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR Apixaban Not studied. Co-administration of The use of boosted PREZISTA Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant anticoagulants may increase (DOAC) that is metabolised by concentrations of the anticoagulant. CYP3A4 and transported by P-gp (CYP3A and/or P-gp inhibition) is not recommended as this may lead to an increased bleeding risk. Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22% Darunavir/cobicistat: darunavir/cobicistat 800/150 mg single Clinical monitoring and dose dose: reduction is required when a dabigatran AUC ↑ 164% DOAC transported by P-gp but not dabigatran Cmax ↑ 164% metabolised by CYP3A4, including dabigatran etexilate and darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with daily: PREZISTA/cobi. dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Ticagrelor Concomitant administration of Based on theoretical considerations, boosted PREZISTA with ticagrelor co-administration of boosted PREZISTA is contraindicated (see section 4.3). with ticagrelor may increase concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition). Clopidogrel Co-administration of clopidogrel Not studied. Co-administration of with boosted PREZISTA is not clopidogrel with boosted PREZISTA is recommended. Use of other expected to decrease clopidogrel active antiplatelets not affected by CYP metabolite plasma concentration, which inhibition or induction (e.g. may reduce the antiplatelet activity of prasugrel) is recommended. clopidogrel. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio boosted PREZISTA. (INR) be monitored when warfarin is combined with boosted PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) cobicistat (HOS-088111) dabigatran (HOS-112096) rivaroxaban (HOS-086236) lead (HOS-085592) clopidogrel (HOS-087927) clarithromycin (HOS-084517) edoxaban (HOS-086234) apixaban (HOS-112091) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) warfarin (HOS-085950)

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58

HOS-116520 · Präparat HOS-094447

Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel clopidogrel with boosted PREZISTA is with boosted PREZISTA is not expected to decrease clopidogrel active recommended. Use of other metabolite plasma concentration, which antiplatelets not affected by CYP may reduce the antiplatelet activity of inhibition or induction (e.g. clopidogrel. prasugrel) is recommended. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio darunavir with low dose ritonavir. (INR) be monitored when warfarin is combined with PREZISTA co-administered with low dose ritonavir. ANTICONVULSANTS Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with Phenytoin are expected to decrease plasma low dose ritonavir should not be concentrations of darunavir and its used in combination with these pharmacoenhancer. medicines. (induction of CYP450 enzymes) Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for 200 mg twice daily carbamazepine Cmin ↑ 54% PREZISTA/ritonavir is carbamazepine Cmax ↑ 43% recommended. If there is a need to darunavir AUC ↔ combine PREZISTA/ritonavir and darunavir Cmin ↓ 15% carbamazepine, patients should be darunavir Cmax ↔ monitored for potential carbamazepine-related adverse events. Carbamazepine concentrations should be monitored and its dose should be titrated for adequate response. Based upon the findings, the carbamazepine dose may need to be reduced by 25% to 50% in the presence of PREZISTA/ritonavir. Clonazepam Not studied. Co-administration of Clinical monitoring is boosted PREZISTA with clonazepam recommended when may increase concentrations of co-administering boosted clonazepam. (CYP3A inhibition) PREZISTA with clonazepam.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521) phenytoin (HOS-084531) warfarin (HOS-085950)

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 97–98

HOS-116609 · Präparat HOS-094447

97  Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22% Darunavir/cobicistat: darunavir/cobicistat 800/150 mg single Clinical monitoring and dose dose: reduction is required when a dabigatran AUC ↑ 164% DOAC transported by P-gp but not dabigatran Cmax ↑ 164% metabolised by CYP3A4, including dabigatran etexilate and darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with daily: PREZISTA/cobi. dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Ticagrelor Based on theoretical considerations, Concomitant administration of co-administration of boosted PREZISTA boosted PREZISTA with ticagrelor with ticagrelor may increase is contraindicated (see section 4.3). concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition). Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel clopidogrel with boosted PREZISTA is with boosted PREZISTA is not expected to decrease clopidogrel active recommended. Use of other metabolite plasma concentration, which antiplatelets not affected by CYP may reduce the antiplatelet activity of inhibition or induction (e.g. clopidogrel prasugrel) is recommended. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio boosted PREZISTA. (INR) be monitored when warfarin is combined with boosted PREZISTA. ANTICONVULSANTS Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with Phenytoin are expected to decrease plasma low dose ritonavir should not be concentrations of darunavir and its used in combination with these pharmacoenhancer. medicines. (induction of CYP450 enzymes) The use of these medicines with PREZISTA/cobicistat is contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) phenobarbital (HOS-085617) cobicistat (HOS-088111) dabigatran (HOS-112096) clopidogrel (HOS-087927) edoxaban (HOS-086234) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)

Wechselwirkungen · Pradaxa

Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-118650 · Präparat HOS-094855

There is no or only limited experience with the following treatments which may increase the risk of bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux, desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)

Wechselwirkungen · Pradaxa

Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 46

HOS-118725 · Präparat HOS-094855

There is no or only limited experience with the following treatments which may increase the risk of bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux, desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)

Wechselwirkungen · Pradaxa

Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 86

HOS-118814 · Präparat HOS-094855

There is no or only limited experience with the following treatments which may increase the risk of bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux, desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)

Wechselwirkungen · Pradaxa

Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 120

HOS-118901 · Präparat HOS-094855

There is no or only limited experience with the following treatments which may increase the risk of bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux, desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)

Gegenanzeigen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 3

HOS-120766 · Präparat HOS-095209

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active pathological bleeding. History of stroke or transient ischaemic attack (TIA). Severe hepatic impairment (Child Pugh class C).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5

HOS-120767 · Präparat HOS-095209

Warfarin: Concomitant administration of Efient with coumarin derivatives other than warfarin has not been studied. Because of the potential for increased risk of bleeding, warfarin (or other coumarin derivatives) and prasugrel should be co-administered with caution (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) warfarin (HOS-085950)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5

HOS-120768 · Präparat HOS-095209

Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant administration with chronic NSAIDs has not been studied. Because of the potential for increased risk of bleeding, chronic NSAIDs (including COX-2 inhibitors) and Efient should be co- administered with caution (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5

HOS-120769 · Präparat HOS-095209

Efient can be concomitantly administered with medicinal products metabolised by cytochrome P450 enzymes (including statins), or medicinal products that are inducers or inhibitors of cytochrome P450 enzymes. Efient can also be concomitantly administered with ASA, heparin, digoxin, and medicinal products that elevate gastric pH, including proton pump inhibitors and H2 blockers. Although not studied in specific interaction studies, Efient has been co-administered in the phase 3 clinical trial with low molecular weight heparin, bivalirudin, and GP IIb/IIIa inhibitors (no information available regarding the type of GP IIb/IIIa inhibitor used) without evidence of clinically significant adverse interactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) heparin (HOS-086930) bivalirudin (HOS-120770)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5

HOS-120771 · Präparat HOS-095209

Effects of other medicinal products on Efient Acetylsalicylic acid: Efient is to be administered concomitantly with acetylsalicylic acid (ASA). Although a pharmacodynamic interaction with ASA leading to an increased risk of bleeding is possible, the demonstration of the efficacy and safety of prasugrel comes from patients concomitantly treated with ASA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5

HOS-120772 · Präparat HOS-095209

Heparin: A single intravenous bolus dose of unfractionated heparin (100 U/kg) did not significantly alter the prasugrel-mediated inhibition of platelet aggregation. Likewise, prasugrel did not significantly alter the effect of heparin on measures of coagulation. Therefore, both medicinal products can be administered concomitantly. An increased risk of bleeding is possible when Efient is co-administered with heparin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin (HOS-086930)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 5–6

HOS-120773 · Präparat HOS-095209

5 Statins: Atorvastatin (80 mg daily) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation. Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6

HOS-120774 · Präparat HOS-095209

Medicinal products that elevate gastric pH: Daily co-administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not change the prasugrel active metabolite’s AUC and Tmax, but decreased the Cmax by 14% and 29%, respectively. In the phase 3 clinical trial, Efient was administered without regard to co-administration of a proton pump inhibitor or H2 blocker. Administration of the 60 mg prasugrel loading dose without concomitant use of proton pump inhibitors may provide most rapid onset of action.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) ranitidine (HOS-085660)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6

HOS-120775 · Präparat HOS-095209

Inhibitors of CYP3A: Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect prasugrel-mediated inhibition of platelet aggregation or the prasugrel active metabolite’s AUC and Tmax, but decreased the Cmax by 34% to 46%. Therefore, CYP3A inhibitors such as azol antifungals, HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin, and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the active metabolite.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) protease (HOS-085623) ciprofloxacin (HOS-085177) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) telithromycin (HOS-084523) clarithromycin (HOS-084517) verapamil (HOS-090602)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6

HOS-120776 · Präparat HOS-095209

Inducers of cytochromes P450: Rifampicin (600 mg daily), a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel. Therefore, known CYP3A inducers such as rifampicin, carbamazepine, and other inducers of cytochromes P450 are not anticipated to have significant effect on the pharmacokinetics of the active metabolite.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618)

Wechselwirkungen · Efient

Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6

HOS-120777 · Präparat HOS-095209

Morphine and other opioids: A delayed and decreased exposure to oral P2Y12 inhibitors, including prasugrel and its active metabolite, has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced prasugrel efficacy in patients co- administered prasugrel and morphine. In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): morphine (HOS-086053)